{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:05:31Z","timestamp":1784174731213,"version":"3.55.0"},"reference-count":29,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Hepatocellular carcinoma (HCC), the most common histological type of primary liver cancer (PLC), remains one of the most consequential malignancies arising in chronic liver disease, in part because its incidence and mortality rates remain closely aligned [...]<\/jats:p>","DOI":"10.3390\/metabo16070499","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T03:34:23Z","timestamp":1784172863000},"page":"499","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Liver Left Behind: GLP-1 Receptor Agonists and the Prospect of Metabolic Adjuvant Therapy After HCC Resection"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9886-0698","authenticated-orcid":false,"given":"Amedeo","family":"Lonardo","sequence":"first","affiliation":[{"name":"Independent Researcher, 41100 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3888-0931","authenticated-orcid":false,"given":"Ralf","family":"Weiskirchen","sequence":"additional","affiliation":[{"name":"Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, D-52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e2445525","DOI":"10.1001\/jamanetworkopen.2024.45525","article-title":"Trends in Hepatocellular Carcinoma Mortality Rates in the US and Projections Through 2040","volume":"7","author":"Qiu","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.20517\/mtod.2022.38","article-title":"Metabolic primary liver cancer in adults: Risk factors and pathogenic mechanisms","volume":"3","author":"Lugari","year":"2023","journal-title":"Metab. Target Organ Damage"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1001378","DOI":"10.37349\/emed.2025.1001378","article-title":"Drug treatment of MASH from none to (too) many","volume":"6","author":"Lonardo","year":"2025","journal-title":"Explor. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.14309\/ajg.0000000000003288","article-title":"Global, Regional, and National Burden of Primary Liver Cancer Attributable to Metabolic Risks: An Analysis of the Global Burden of Disease Study 1990\u20132021","volume":"120","author":"Wu","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.32604\/biocell.2026.076177","article-title":"Obesity, Metabolic Dysfunction-Associated Steatotic Liver Disease and Hepatocellular Carcinoma: How Molecular Changes Impact Cellular Functions","volume":"50","author":"Weiskirchen","year":"2026","journal-title":"Biocell"},{"key":"ref_6","first-page":"34","article-title":"From algorithm to dialogue: Interpreting the 2026 BCLC-CUSE strategy for HCC care","volume":"12","author":"Weiskirchen","year":"2026","journal-title":"Hepatoma Res."},{"key":"ref_7","first-page":"40","article-title":"Metabolic dysfunction-associated steatotic liver disease: A key factor in hepatocellular carcinoma therapy response","volume":"4","year":"2024","journal-title":"Metab. Target Organ Damage"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"107675","DOI":"10.4254\/wjh.v17.i7.107675","article-title":"Link between type 2 diabetes mellitus and hepatocellular carcinoma","volume":"17","author":"Giri","year":"2025","journal-title":"World J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Wang, Y.-G., Wang, P., Wang, B., Fu, Z.-J., Zhao, W.-J., and Yan, S.-L. (2014). Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: A systematic review and meta-analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0095485"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejso.2021.08.010","article-title":"Association of type 2 diabetes mellitus with incidences of microvascular invasion and survival outcomes in hepatitis B virus-related hepatocellular carcinoma after liver resection: A multicenter study","volume":"48","author":"Zhang","year":"2022","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): A phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"IMbrave050 investigators. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): A randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jhep.2026.01.006","article-title":"Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma","volume":"84","author":"Yopp","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/HEP.0000000000001269","article-title":"Critical Update: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"82","author":"Taddei","year":"2025","journal-title":"Hepatology"},{"key":"ref_15","unstructured":"European Association for the Study of the Liver (2025). EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J. Hepatol., 82, 315\u2013374."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Cho, W.R., Wang, C.C., Tsai, M.Y., Chou, C.K., Liu, Y.W., Wu, Y.J., Lin, M.T., Chen, K.D., Chuang, C.H., and Huang, P.Y. (2021). Impact of metformin use on the recurrence of hepatocellular carcinoma after initial liver resection in diabetic patients. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0247231"},{"key":"ref_17","first-page":"80","article-title":"Impact of Diabetes Mellitus and Obesity Comorbidities on Survival Outcomes after Hepatocellular Carcinoma Resection: A Multicenter Retrospective Study","volume":"14","author":"Shinkawa","year":"2024","journal-title":"Liver Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Xiang, Y.-J., Liu, Z.-H., Feng, J.-K., Qin, Y.-Y., Yu, H.-M., Cheng, Y.-Q., Chen, G., Wu, J.-Y., Zeng, Y.-Y., and Tang, Y.-F. (2026). Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: A target trial emulation study. Gut, Epub ahead of printing.","DOI":"10.1136\/gutjnl-2026-338462"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Du, J., Xi, L., Zhang, Z., Ge, X., Li, W., Peng, W., Jiang, X., Liu, W., Zhao, N., and Wang, X. (2023). Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1097612"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/jcmm.13984","article-title":"The relationship between phospholipids and insulin resistance: From clinical to experimental studies","volume":"23","author":"Chang","year":"2019","journal-title":"J. Cell. Mol. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00125-021-05611-3","article-title":"Associations of plasma glycerophospholipid profile with modifiable lifestyles and incident diabetes in middle-aged and older Chinese","volume":"65","author":"Chen","year":"2022","journal-title":"Diabetologia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.atherosclerosis.2009.05.029","article-title":"Metabolism and atherogenic disease association of lysophosphatidylcholine","volume":"208","author":"Schmitz","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.talanta.2015.10.070","article-title":"Metabolomic profile related to cardiovascular disease in patients with type 2 diabetes mellitus: A pilot study","volume":"148","author":"Navarro","year":"2016","journal-title":"Talanta"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Zhang, L., Hu, Y., An, Y., Wang, Q., Liu, J., and Wang, G. (2022). The Changes of Lipidomic Profiles Reveal Therapeutic Effects of Exenatide in Patients With Type 2 Diabetes. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.677202"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100453","DOI":"10.1016\/j.metop.2026.100453","article-title":"Baseline metabolite profiles predict the glucose-lowering efficacy of exenatide in patients with type 2 diabetes","volume":"29","author":"Le","year":"2026","journal-title":"Metab. Open"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Alfadda, A.A., Rahman, A.M.A., Benabdelkamel, H., AlMalki, R., Alsuwayni, B., Alhossan, A., Aldhwayan, M.M., Abdeen, G.N., Miras, A.D., and Masood, A. (2024). Metabolomic Effects of Liraglutide Therapy on the Plasma Metabolomic Profile of Patients with Obesity. Metabolites, 14.","DOI":"10.3390\/metabo14090500"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e71434","DOI":"10.1002\/cam4.71434","article-title":"Glucagon-Like Peptide-1 Receptor Agonists and Hepatocellular Carcinoma Prevention: A Meta-Analysis and Clinical Decision Framework","volume":"14","author":"Dalbeni","year":"2025","journal-title":"Cancer Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e002395","DOI":"10.1136\/bmjdrc-2021-002395","article-title":"Ceramides and phospholipids are downregulated with liraglutide treatment: Results from the LiraFlame randomized controlled trial","volume":"9","author":"Zobel","year":"2021","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12944-023-01922-z","article-title":"Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: A post hoc analysis of two randomized clinical trials","volume":"22","author":"Wretlind","year":"2023","journal-title":"Lipids Health Dis."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/7\/499\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:00:10Z","timestamp":1784174410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/7\/499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":29,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["metabo16070499"],"URL":"https:\/\/doi.org\/10.3390\/metabo16070499","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]}}}